Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeff Michalski

Radiation Oncology Saint Louis, MO Medical Doctor

NPI 1902824410 CMS profile 221723

4921 Parkview Pl, Dept Radiation Oncology, Ll, Saint Louis, MO 63110

Open in the dashboard

General payments

$44,480

79 records reported · program years 2019–2025

Research payments

$1,260

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$583,468 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeff Michalski of Saint Louis, MO is reported in the CMS Open Payments database as having received $44,480 across 79 general payments and $1,260 in research payments paid to them. Separately, studies naming them as principal investigator received $583,468 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $990 9
2025 Research $576 1
2024 General $331 5
2024 Research $683 2
2023 General $278 3
2022 General $299 3
2021 General $5,199 11
2020 General $4,250 3
2019 General $33,131 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeff Michalski
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Jeff Michalski were reported at $990. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Jeff Michalski Radiation Oncology median Middle half National median
2019 $33,131 $138 $48–$462 $163
2020 $4,250 $79 $26–$262 $114
2021 $5,199 $119 $37–$358 $132
2022 $299 $139 $43–$424 $149
2023 $278 $167 $57–$473 $160
2024 $331 $168 $56–$541 $164
2025 $990 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $24,424 37 payments
  2. Merck Sharp & Dohme Corporation $7,693 10 payments
  3. Augmenix, Inc. $6,720 3 payments
  4. Novartis Pharmaceuticals Corporation $3,083 2 payments
  5. Bioprotect Medical, Inc. $801 5 payments
  6. Siemens Medical Solutions USA, Inc. $587 9 payments
  7. Mevion_Medical_Systems_Inc $378 5 payments
  8. Viewray Technologies Inc $231 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $219 2 payments
  10. Janssen Scientific Affairs, LLC $125 1 payment
  11. Other $218 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $30,208 11 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,394 3 payments
  3. Food and Beverage $4,606 48 payments
  4. Travel and Lodging $4,262 16 payments
  5. Gift $10 1 payment
Products named General payments · program years 2019–2025
  1. General BPH $9,146 9 payments
  2. SpaceOAR Oncology $6,720 3 payments
  3. SPACEOAR Bph $6,528 8 payments
  4. General Therapies Therapies $5,580 7 payments
  5. SPACEOAR VUE $1,644 4 payments
  6. BIOPROTECT BALLOON IMPLANT SYSTEM $801 5 payments
  7. GENERAL THERAPIES General Therapies $525 2 payments
  8. GENERAL - BPH $500 1 payment
  9. PTS250 $378 5 payments
  10. Varian Ethos Treatment Planning $257 4 payments
  11. Other $1,448 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,260 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

280

Median for Radiation Oncology: 65

Drug cost

$6,016

Median for Radiation Oncology: $978

Branded share of claims

4.6%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abiraterone Acetate Generic 22 $3,312
Bicalutamide Generic 46 $1,298
Tamsulosin Hcl Generic 130 $1,041
Ciprofloxacin Hcl Generic 69 $250
Venlafaxine Hcl Er Venlafaxine Hcl Brand 13 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$140,304

Medicare's payments for the services billed

Medicare patients

221

Average age 74

Services billed

2,176

17 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 71%
Arthritis 40%
Diabetes 28%
Ischemic heart disease 27%
Chronic kidney disease 24%
Atrial fibrillation 19%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record